Eli Lilly halts COVID-19 antibody treatment trial over safety issues
Category: #headlines  | By Nikita Chaurasia  | Date: 2020-10-15 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly halts COVID-19 antibody treatment trial over safety issues

 

  • The announcement comes along the heels of a sudden spike in the number of coronavirus cases across U.S.
  • Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials.

Eli Lilly and Company, an American pharmaceutical company, has reportedly announced that it has paused its government sponsored COVID-19 antibody treatment trial over safety concerns. Sources close to the matter stated that the announcement comes along the heels of a sudden spike in the number of coronavirus cases across United States.

For the record, Eli Lilly’s COVID-19 antibody study will focus on the benefits of the therapy on various patients suffering from the novel coronavirus. Besides the potential antibody, each participant has reportedly also received an experimental drug called remdesivir which is commonly used to treat COVID-19 patients.

It is to be noted that the company had recently requested for an EUA (emergency use authorization) for its antibody LY-CoV555 from the U.S. Food & Drug Association (FDA). However, the exact safety concerns which halted the trials remain unclear, sources claimed.

Molly McCully, a spokesperson from Eli Lilly mentioned in a comment that the ACTIV-3 data safety monitoring board (DSMB) suggested the company to halt the trials. She further added that the Eli Lilly supported the decision made by the independent DSMB for the wellbeing of the study participants.

According to industry experts, such pauses during large scale clinical trials are not an uncommon instance and the decline in the volunteer’s health is not necessarily due to the vaccine or an experimental drug. In fact, such study halts enable scientific experts to review the data generated during the trials.

Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials, cited sources with relevant information.

In other news, another American pharmaceutical company, Johnson & Johnson, had reportedly paused its study for COVID-19 antibody candidate after one of the trial participants witnessed an unexpected illness.

Source- https://www.aljazeera.com/economy/2020/10/13/eli-lilly-pauses-covid-19-antibody-trial-due-to-safety-concern

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...

Legato opens 80 new jobs in its Limerick Research & Development hub

Legato opens 80 new jobs in its Limerick Research & Development hub

By Nikita Chaurasia

The global capability center of a leading U.S. health care insurance company, Legato Health Technologies is planning to build an additional 80 posts at its Limerick facility. It would bring the total number of staff to 200, which the fir...